tetano
Editor, Senior Moderator
PLoS Pathog
. 2025 Jan 23;21(1):e1012903.
doi: 10.1371/journal.ppat.1012903. Online ahead of print. Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies
Peter R McIlroy[SUP] 1 [/SUP], Le Thanh Mai Pham[SUP] 2 [/SUP], Thomas Sheffield[SUP] 3 [/SUP], Maxwell A Stefan[SUP] 1 [/SUP], Christine E Thatcher[SUP] 1 [/SUP], James Jaryenneh[SUP] 1 [/SUP], Jennifer L Schwedler[SUP] 1 [/SUP], Anupama Sinha[SUP] 1 [/SUP], Christopher A Sumner[SUP] 1 [/SUP], Iris K A Jones[SUP] 4 [/SUP], Stephen Won[SUP] 1 [/SUP], Ryan C Bruneau[SUP] 1 [/SUP], Dina R Weilhammer[SUP] 5 [/SUP], Zhuoming Liu[SUP] 6 [/SUP], Sean Whelan[SUP] 6 [/SUP], Oscar A Negrete[SUP] 4 [/SUP], Kenneth L Sale[SUP] 3 [/SUP], Brooke Harmon[SUP] 1 [/SUP]
Affiliations
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to persist, demonstrating the risks posed by emerging infectious diseases to national security, public health, and the economy. Development of new vaccines and antibodies for emerging viral threats requires substantial resources and time, and traditional development platforms for vaccines and antibodies are often too slow to combat continuously evolving immunological escape variants, reducing their efficacy over time. Previously, we designed a next-generation synthetic humanized nanobody (Nb) phage display library and demonstrated that this library could be used to rapidly identify highly specific and potent neutralizing heavy chain-only antibodies (HCAbs) with prophylactic and therapeutic efficacy in vivo against the original SARS-CoV-2. In this study, we used a combination of high throughput screening and machine learning (ML) models to identify HCAbs with potent efficacy against SARS-CoV-2 viral variants of interest (VOIs) and concern (VOCs). To start, we screened our highly diverse Nb phage display library against several pre-Omicron VOI and VOC receptor binding domains (RBDs) to identify panels of cross-reactive HCAbs. Using HCAb affinity for SARS-CoV-2 VOI and VOCs (pre-Omicron variants) and model features from other published data, we were able to develop a ML model that successfully identified HCAbs with efficacy against Omicron variants, independent of our experimental biopanning workflow. This biopanning informed ML approach reduced the experimental screening burden by 78% to 90% for the Omicron BA.5 and Omicron BA.1 variants, respectively. The combined approach can be applied to other emerging viruses with pandemic potential to rapidly identify effective therapeutic antibodies against emerging variants.
. 2025 Jan 23;21(1):e1012903.
doi: 10.1371/journal.ppat.1012903. Online ahead of print. Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies
Peter R McIlroy[SUP] 1 [/SUP], Le Thanh Mai Pham[SUP] 2 [/SUP], Thomas Sheffield[SUP] 3 [/SUP], Maxwell A Stefan[SUP] 1 [/SUP], Christine E Thatcher[SUP] 1 [/SUP], James Jaryenneh[SUP] 1 [/SUP], Jennifer L Schwedler[SUP] 1 [/SUP], Anupama Sinha[SUP] 1 [/SUP], Christopher A Sumner[SUP] 1 [/SUP], Iris K A Jones[SUP] 4 [/SUP], Stephen Won[SUP] 1 [/SUP], Ryan C Bruneau[SUP] 1 [/SUP], Dina R Weilhammer[SUP] 5 [/SUP], Zhuoming Liu[SUP] 6 [/SUP], Sean Whelan[SUP] 6 [/SUP], Oscar A Negrete[SUP] 4 [/SUP], Kenneth L Sale[SUP] 3 [/SUP], Brooke Harmon[SUP] 1 [/SUP]
Affiliations
- PMID: 39847604
- DOI: 10.1371/journal.ppat.1012903
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to persist, demonstrating the risks posed by emerging infectious diseases to national security, public health, and the economy. Development of new vaccines and antibodies for emerging viral threats requires substantial resources and time, and traditional development platforms for vaccines and antibodies are often too slow to combat continuously evolving immunological escape variants, reducing their efficacy over time. Previously, we designed a next-generation synthetic humanized nanobody (Nb) phage display library and demonstrated that this library could be used to rapidly identify highly specific and potent neutralizing heavy chain-only antibodies (HCAbs) with prophylactic and therapeutic efficacy in vivo against the original SARS-CoV-2. In this study, we used a combination of high throughput screening and machine learning (ML) models to identify HCAbs with potent efficacy against SARS-CoV-2 viral variants of interest (VOIs) and concern (VOCs). To start, we screened our highly diverse Nb phage display library against several pre-Omicron VOI and VOC receptor binding domains (RBDs) to identify panels of cross-reactive HCAbs. Using HCAb affinity for SARS-CoV-2 VOI and VOCs (pre-Omicron variants) and model features from other published data, we were able to develop a ML model that successfully identified HCAbs with efficacy against Omicron variants, independent of our experimental biopanning workflow. This biopanning informed ML approach reduced the experimental screening burden by 78% to 90% for the Omicron BA.5 and Omicron BA.1 variants, respectively. The combined approach can be applied to other emerging viruses with pandemic potential to rapidly identify effective therapeutic antibodies against emerging variants.